Patterns of longitudinal cortical atrophy over 3 years in empirically derived MCI subtypes (original) (raw)

Abstract

Objective

We previously identified 4 empirically derived mild cognitive impairment (MCI) subtypes via cluster analysis within the Alzheimer's Disease Neuroimaging Initiative (ADNI) and demonstrated high correspondence between patterns of cortical thinning at baseline and each cognitive subtype. We aimed to determine whether our MCI subtypes demonstrate unique longitudinal atrophy patterns.

Methods

ADNI participants (295 with MCI and 134 cognitively normal [CN]) underwent annual structural MRI and neuropsychological assessments. General linear modeling compared vertex-wise differences in cortical atrophy rates between each MCI subtype and the CN group. Linear mixed models examined trajectories of cortical atrophy over 3 years within lobar regions of interest.

Results

Compared to the CN group, those with amnestic MCI (memory deficit) initially demonstrated greater atrophy rates within medial temporal lobe regions that became more widespread over time. Those with dysnomic/amnestic MCI (naming/memory deficits) showed greater atrophy rates largely localized to temporal lobe regions. The mixed MCI (impairment in all cognitive domains) group showed greater atrophy rates in widespread regions at all time points. The cluster-derived normal group, who had intact neuropsychological performance and normal cortical thickness at baseline despite their MCI diagnosis via conventional diagnostic criteria, continued to show normal cognition and minimal cortical atrophy over 3 years.

Conclusions

ADNI's purported amnestic MCI sample produced more refined cognitive subtypes with unique longitudinal cortical atrophy rates. These novel MCI subtypes reliably reflect underlying atrophy, reduce false-positive diagnostic errors, and improve prediction of clinical course. Such improvements have implications for the selection of participants for clinical trials and for providing more precise risk assessment for individuals diagnosed with MCI.

Get full access to this article

View all available purchase options and get full access to this article.

References

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.

Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183–194.

Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005;62:1160–1163.

Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–246.

Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010;74:201–209.

Edmonds EC, Delano-Wood L, Clark LR, et al. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement 2015;11:415–424.

Bangen KJ, Clark AL, Werhane M, et al. Cortical amyloid burden differences across empirically-derived mild cognitive impairment subtypes and interaction with APOE ε4 genotype. J Alzheimers 2016;52:849–861.

Edmonds EC, Eppig J, Bondi MW, et al. Heterogeneous cortical atrophy patterns in MCI not captured by conventional diagnostic criteria. Neurology 2016;87:2108–2116.

Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968–980.

Holland D, Dale AM. Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal 2011;15:489–497.

Fischl B, Sereno MI, Tootell RB, Dale AM. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp 1999;8:272–284.

Singer JD, Willett JB. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York: Oxford University Press; 2003.

Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol 2009;65:403–413.

Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ. Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease. Brain 2006;129:2885–2893.

Whitwell JL, Petersen RC, Negash S, et al. Patterns of atrophy differ among specific subtypes of mild cognitive impairment. Arch Neurol 2007;64:1130–1138.

Whitwell JL, Shiung MM, Przybelski BS, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2008;70:512–520.

Edmonds EC, McDonald CR, Marshall A, et al. Early versus late MCI: improved MCI staging using a neuropsychological approach. Alzheimers Dement 2019;15:699–708.

Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathological process of Alzheimer's disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70:960–969.

Thomas KR, Edmonds EC, Delano-Wood L, Bondi MW. Longitudinal trajectories of informant-reported daily functioning in empirically defined subtypes of mild cognitive impairment. J Int Neuropsychol Soc 2017;23:521–527.

Edmonds EC, Weigand AJ, Thomas KR, et al. Increasing inaccuracy of self-reported subjective cognitive complaints over 24 months in empirically derived subtypes of mild cognitive impairment. J Int Neuropsychol Soc 2018;24:842–853.

Brooks BL, Iverson GL, Holdnack JA, Feldman HH. Potential for misclassification of mild cognitive impairment: a study of memory scores on the Wechsler Memory Scale-III in healthy older adults. J Int Neuropsychol Soc 2008;14:463–478.

Bondi MW, Edmonds EC, Jak AJ, et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and prediction of progression. J Alzheimers Dis 2014;42:275–289.

Lenehan ME, Klekociuk SZ, Summers MJ. Absence of a relationship between subjective memory complaint and objective memory impairment in mild cognitive impairment (MCI): is it time to abandon subjective memory complaint as an MCI diagnostic criterion? Int Psychogeriatr 2012;24:1505–1514.

Clark LR, Delano-Wood L, Libon DJ, et al. Are empirically derived subtypes of mild cognitive impairment consistent with conventional subtypes? J Int Neuropsychol Soc 2013;19:635–645.

Edmonds EC, Ard MC, Edland SD, Galasko DR, Salmon DP, Bondi MW. Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: a secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement 2017;4:11–18.

Eppig JS, Edmonds EC, Campbell L, Sanderson-Cimino M, Delano-Wood L, Bondi WM. Statistically derived subtypes and associations with cerebrospinal fluid and genetic biomarkers in mild cognitive impairment: a latent profile analysis. J Int Neuropsychol Soc 2017;23:564–576.

Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickerson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011;10:785–796.

Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–2388.

Cash DM, Ridgway GR, Liang Y, et al. The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. Neurology 2013;81:1425–1433.

Pini L, Pievani M, Bocchetta M, et al. Brain atrophy in Alzheimer's disease and aging. Aging Res Rev 2016;30:25–48.

McDonald CR, Gharapetian L, McEvoy LK, et al. Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment. Neurobiol Aging 2012;33:242–253.

Machulda MM, Lundt ES, Albertson SM, et al. Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. Alzheimers Dement 2019;15:878–887.